"The guest argued that active stock pickers will significantly outperform passive index funds due to extreme market valuations and an impending demographic shift to passive selling."

"The guest argued that measuring a company's lobbying spend relative to its size is a powerful, quantifiable factor for predicting stock outperformance."

"The guest argued that investors should focus on simple, consistent cash-flow businesses in the consumer sector rather than high-beta, cyclical discretionary names."

"The guest argued that China has surpassed the United States in clinical trial volume and novel drug development, shifting the global center of gravity for biotechnology."